PCC
TRIB

Park Circle Company’s Trinity Biotech TRIB Stock Holding History

Park Circle Company’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27
Closed -$24K – 91
2017
Q1 		$24K Hold
27
– – 0.02% 79
2016
Q4 		$28K Buy
27
+7
+35% +$7.23K 0.02% 86
2016
Q3 		$40K Hold
20
– – 0.03% 80
2016
Q2 		$34K Hold
20
– – 0.02% 76
2016
Q1 		$35K Buy
20
+12
+150% +$19.1K 0.03% 73
2015
Q4 		$14K Buy
+8
New +$14.2K 0.01% 89

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Park Circle Company's TRIB Position: Q2 2017 in Review

Park Circle Company sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 27 shares — an estimated $24K sold.

Park Circle Company first reported a position in TRIB in Q4 2015 and held it in 6 quarters. The position peaked at $40K in Q3 2016. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • Park Circle Company reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • Park Circle Company sold 27 Trinity Biotech shares in Q2 2017, an estimated $24K.
  • Park Circle Company first reported a position in Trinity Biotech in Q4 2015 and held it in 6 quarters.
  • Park Circle Company's Trinity Biotech position peaked at $40K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Park Circle Company's 13F filing for Q2 2017, filed 8 Aug 2017.